• Han Wang, Xiuqi Li, Xingan Wu, Huiting Wu, Gang Xie, and Hui Wang.
• Department of Cardiology, General Hospital of the Yangtze River Shipping, Wuhan, Hubei, China.
• Medicine (Baltimore). 2022 Feb 11; 101 (6): e28779e28779.

BackgroundCoronary artery disease (CAD) is among the main causes of morbidities and mortalities globally. It is also considered to be an outcome of acute thrombotic events which entail activating platelets as well as coagulation proteins. In particular, rivaroxaban along with aspirin have been considered to reduce thrombotic events. However, they are yet to be evaluated by combining with or putting them against each other in patients experiencing CAD. This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD.Methods And AnalysisWe intend to search information from the following databases: MEDLINE, EMBASE, Web of Science, Cochrane library, WanFang, and China National Knowledge Infrastructure. In the search, we intend to regard randomized control trials written in either English or Chinese and only those published until December 2021, as well as only those that have assessed the effectiveness and safety of combining rivaroxaban and aspirin in treating patients suffering from chronic CAD. We intend to accompany the study identification with searching or relevant reference lists as well as citations. We will also contact respective authors to provide additional information or data were needful. From the search, we will collate all citations identified and remove all duplicates. Similarly, 2 independent authors will screen all the titles and abstracts and assess them against the inclusion criteria for the study. Only selected studies will be included for critical appraisal, extraction of data, and synthesis. We will then conduct statistical analyses by utilizing a random-effect model.Ethics And DisseminationThis study does not require ethical approval as the findings will be published in a peer-review journal.Registration Number10.17605/OSF.IO/WBGE4.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…